Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
Frontiers | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Immunotherapy and its side effects | Cancer Research UK
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma | NEJM Evidence
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial ...
Management of Long-Term Immune-Related Toxicities Needed in NSCLC - ILCN.org (ILCN/WCLC)
IJMS | Free Full-Text | Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer | ONS
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer | Future Oncology
Immune-checkpoint inhibitors: long-term implications of toxicity | Nature Reviews Clinical Oncology
Reimagining Treatment for Unresectable Stage III Non-Small Cell Lung Cancer - Cancer Therapy Advisor
GeparNUEVO: durvalumab plus neoadjuvant chemotherapy in TNBC demonstrates long-term clinical benefit - Onco Americas
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Imfinzi Duravalumab Injection, 500 mg/10 mL at Rs 8999/box in New Delhi | ID: 2853132773630
Did You Know – IMFINZI® (durvalumab) for unresectable Stage 3 NSCLC
Long-Term Side Effects of Immune Checkpoint Inhibitors - NCI
Tremelimumab-actl (Imjudo) Drug Information
Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA | Clinical Drug Investigation
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma | NEJM Evidence
Side-effects of Short Term and Long Term Glucocortcoid Use | Download Table
Durvalumab (Imfinzi) Drug Information
Immune-checkpoint inhibitors: long-term implications of toxicity | Nature Reviews Clinical Oncology
Tremelimumab/Durvalumab Plus Chemo Improves Survival in Metastatic NSCLC
Does immunotherapy have side effects? | MD Anderson Cancer Center
